ACST Stock – (NASDAQ: ACST) is providing an update on the use

ACST Stock – (NASDAQ: ACST) is giving an update on the use

ACST
-1.84%
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is giving an update on the use of its “at the market” equity offering program.

As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to put into practice an “at-the market” equity offering program under which Acasti may issue and market from time to time its common shares having an aggregate offering price of up to $75 million throughout the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January 27, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares had been offered at prevailing market costs averaging US$1.0747 per share. No securities had been sold throughout the facilities of the TSXV or, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333-239538) as made effective on July 7, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a result of the latest ATM sales, Acasti has a total of 200,119,659 typical shares issued and superb as of March five, 2021.

The extra capital raised has strengthened Acasti’s balance sheet and will provide the Company with more flexibility in its ongoing review process to enjoy and evaluate strategic alternatives.

Approximately Acasti – ACST Stock

Acasti is actually a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescription medications making use of OM3 greasy acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical evidence of efficacy as well as safety for lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being developed for individuals with serious HTG.

Forward Looking Statements – ACST Stock

Statements of that press release that aren’t statements of current or historical fact constitute “forward-looking information” to the meaning of Canadian securities laws and “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward-looking assertions include known and unknown risks, uncertainties, along with other unknown components that can result in the actual outcomes of Acasti to be materially different from historical success and from any future outcomes expressed or even implied by such forward-looking statements. In addition to statements which explicitly describe such risks as well as uncertainties, readers are urged to give some thought to statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be uncertain and forward-looking. People are actually cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the date of this press release. Forward-looking claims in this press release include, but are not limited to, information or statements concerning Acasti’s strategy, future operations and its review of strategic alternatives.

The forward-looking assertions contained in this specific press release are expressly qualified in the entirety of theirs by this alerting declaration, the “Special Note Regarding Forward Looking Statements” area in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com as well as on the investor area of Acasti’s site at www.acastipharma.com. All forward-looking assertions in that press release exist as of the particular date of this particular press release.

ACST Stock – Acasti does not undertake to upgrade some such forward looking statements whether as a consequence of new information, future events or otherwise, except as required by law. The forward looking assertions contained herein are also subject generally to assumptions and risks as well as uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities and The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is giving an update on the use

Scroll to top